TrialPharmacology research & perspectives2020

An integrated assessment of the ADME properties of the CDK4/6 Inhibitor ribociclib utilizing preclinical in vitro, in vivo, and human ADME data.

Alexander D James et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.